2018
Cross-sensitivity of psychiatric and behavioral side effects with antiepileptic drug use
Chen B, Choi H, Hirsch LJ, Legge A, Buchsbaum R, Detyniecki K. Cross-sensitivity of psychiatric and behavioral side effects with antiepileptic drug use. Seizure 2018, 62: 38-42. PMID: 30273800, DOI: 10.1016/j.seizure.2018.09.014.Peer-Reviewed Original ResearchConceptsBehavioral side effectsMore antiepileptic drugsAntiepileptic drugsSide effectsAdult patientsSpecific antiepileptic drugsAntiepileptic drug useCertain antiepileptic drugsHistory of depressionAED usePatientsDrug useSignificant predictorsSignificant increasePsychosisDepressionZNSConfoundersEpilepsyDose
2017
Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy
Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, Detyniecki K. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior 2017, 76: 24-31. PMID: 28931473, DOI: 10.1016/j.yebeh.2017.08.039.Peer-Reviewed Original ResearchConceptsBehavioral side effectsSide effectsPractice-based sampleAntiepileptic drug useHigh rateAED regimenAdult patientsNewer AEDsCessation ratesAntiepileptic drugsIntractable epilepsyMedical historyAbsence seizuresMedical recordsPhysician reportsAED usePatientsLevetiracetamDepressive moodDrug useGabapentinLamotriginePatient recordsSuicidal thoughtsPhenytoin
2016
Assessment of Treatment Side Effects and Quality of Life in People with Epilepsy
Blond BN, Detyniecki K, Hirsch LJ. Assessment of Treatment Side Effects and Quality of Life in People with Epilepsy. Neurologic Clinics 2016, 34: 395-410. PMID: 27086986, DOI: 10.1016/j.ncl.2015.11.002.Peer-Reviewed Original Research
2015
Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: An extended follow-up
Javed A, Cohen B, Detyniecki K, Hirsch LJ, Legge A, Chen B, Bazil C, Kato K, Buchsbaum R, Choi H. Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: An extended follow-up. Seizure 2015, 29: 34-40. PMID: 26076842, DOI: 10.1016/j.seizure.2015.03.013.Peer-Reviewed Original ResearchConceptsCognitive side effectsAntiepileptic medicationsSide effectsMultiple logistic regression analysisMore antiepileptic medicationsLogistic regression analysisQuality of lifeIndependent predictorsRetrospective studyAntiepileptic drugsAdult outpatientsMedical recordsAdverse effectsIntellectual disabilityPolytherapyLevetiracetamGabapentinRegression analysisLamotrigineLower ratesPredictorsCarbamazepineMonotherapyMedicationsRelative frequency
2011
The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy
Arif H, Svoronos A, Resor SR, Buchsbaum R, Hirsch LJ. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia 2011, 52: 1905-1913. PMID: 21838791, DOI: 10.1111/j.1528-1167.2011.03217.x.Peer-Reviewed Original ResearchConceptsLTG clearanceOlder adultsYoung adultsOlder patientsSeizure freedomYounger patientsAdverse effectsOne-year retentionEfficacy of lamotrigineIntolerable side effectsHigher serum levelsSpecific adverse effectsSignificant adverse effectsLamotrigine clearanceEffect of ageApparent clearanceSerum levelsLTG levelsOldest tertileAdult outpatientsSide effectsPatientsLamotrigineEnzyme inducersIntolerability
2008
Patient-reported cognitive side effects of antiepileptic drugs: Predictors and comparison of all commonly used antiepileptic drugs
Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR, Hirsch LJ. Patient-reported cognitive side effects of antiepileptic drugs: Predictors and comparison of all commonly used antiepileptic drugs. Epilepsy & Behavior 2008, 14: 202-209. PMID: 19010446, DOI: 10.1016/j.yebeh.2008.10.017.Peer-Reviewed Original ResearchConceptsCognitive side effectsAntiepileptic drugsSide effectsMore antiepileptic drugsWeeks of therapyNonrandomized retrospective studyRetrospective studyMedical recordsAdult outpatientsMultivariate analysisZonisamidePatientsGabapentinLamotrigineDrugsLevetiracetamTopiramateOxcarbazepinePhenytoinCarbamazepinePredictorsMonotherapyOutpatientsEpilepsyTherapyLevitating Levetiracetam's Status for Status Epilepticus
Hirsch LJ. Levitating Levetiracetam's Status for Status Epilepticus. Epilepsy Currents 2008, 8: 125-126. PMID: 18852834, PMCID: PMC2566612, DOI: 10.1111/j.1535-7511.2008.00266.x.Peer-Reviewed Original ResearchTreatment of SEStatus epilepticusBenzodiazepine-refractory status epilepticusRefractory focal status epilepticusNew anticonvulsive drugsRefractory status epilepticusFocal status epilepticusSevere side effectsCombination of drugsIntravenous levetiracetamAntiepileptic medicationsOral medicationsAnticonvulsive drugsIntravenous formulationSide effectsPatientsEpileptic seizuresEpilepticusMedicationsLevetiracetamTreatmentDrugsEpisodesStatusSeizures
2007
The Status of Intravenous Valproate for Status
Hirsch LJ. The Status of Intravenous Valproate for Status. Epilepsy Currents 2007, 7: 96-98. PMID: 17694164, PMCID: PMC1941916, DOI: 10.1111/j.1535-7511.2007.00185.x.Peer-Reviewed Original Research
2006
Topiramate for the treatment of epilepsy and other nervous system disorders
van Passel L, Arif H, Hirsch LJ. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Review Of Neurotherapeutics 2006, 6: 19-31. PMID: 16466308, DOI: 10.1586/14737175.6.1.19.Peer-Reviewed Original ResearchConceptsPossible neuroprotective agentsTroublesome adverse effectsOral hypoglycemic agentsCognitive side effectsTreatment of epilepsyNervous system disordersNeuropathic painMigraine prophylaxisNeuroprotective agentsHypoglycemic agentsSystem disordersSide effectsBroad-spectrum efficacyBipolar disorderLow dosesPsychiatric conditionsTopiramateSubstance dependenceAdverse effectsEpilepsyDisordersEfficacySpectrum efficacyMonotherapyProphylaxis
2004
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy
Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR, Morrell MJ. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004, 63: 1022-1026. PMID: 15452293, DOI: 10.1212/01.wnl.0000138424.33979.0c.Peer-Reviewed Original ResearchMeSH KeywordsAnticonvulsantsDose-Response Relationship, DrugDrug EruptionsDrug InteractionsDrug Therapy, CombinationEpilepsyFemaleGastrointestinal DiseasesHeadacheHumansLamotrigineMaleMental DisordersNervous System DiseasesRetrospective StudiesSleep Initiation and Maintenance DisordersTriazinesValproic AcidConceptsLamotrigine serum concentrationsSpecific side effectsAntiepileptic drugsSide effectsSerum levelsLTG levelsSerum concentrationsColumbia Comprehensive Epilepsy CenterConcomitant antiepileptic drugsLTG serum levelsComprehensive Epilepsy CenterRates of toxicityDuration of useInitial target rangeAED regimensRefractory patientsToxic regimenConcurrent medicationsSeizure freedomAdditional efficacyClinical toxicityEpilepsy centersLTG concentrationsClinical trialsDose changes